SCHEMBL4943612

SCHEMBL4943612

COC(=O)c1ccc(-c2ccc(OC)cc2)o1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.57
MAPT P10636 3/20 0.57
KDM4E B2RXH2 2/20 0.57
PKM P14618 2/20 0.57
CYP1A2 P05177 1/20 0.57
CYP3A4 P08684 1/20 0.57
CYP2D6 P10635 1/20 0.57
CYP2C9 P11712 1/20 0.57
HPGD P15428 1/20 0.57
CYP2C19 P33261 1/20 0.57
HSD17B10 Q99714 1/20 0.57
PDE4B Q07343 4/20 0.55
MGAM O43451 2/20 0.54
GAA P10253 2/20 0.54
SI P14410 2/20 0.54
MGAM2 Q2M2H8 2/20 0.54
MEN1 O00255 1/20 0.54
POLB P06746 1/20 0.54
THRB P10828 1/20 0.54
KMT2A Q03164 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4943742 0.84 HTT (0.51) ALDH1A1MAPTKDM4ECYP1A2HPGD
SCHEMBL4896906 0.84 ALDH1A1 (0.66) ALDH1A1MAPTKDM4EPKMCYP1A2
SCHEMBL25002889 0.84 ABCB1 (0.51) ALDH1A1MAPTKDM4EPKMCYP1A2
SCHEMBL13485760 0.83 ALDH1A1 (0.59) ALDH1A1MAPTKDM4EPKMCYP1A2
SCHEMBL21981938 0.83 HTT (0.67) ALDH1A1MAPTKDM4ECYP1A2CYP2C9
SCHEMBL22066403 0.83 HPGD (0.56) ALDH1A1MAPTKDM4ECYP1A2CYP2C9
SCHEMBL1143497 0.83 ALDH1A1 (0.50) ALDH1A1MAPTKDM4ECYP1A2HPGD
SCHEMBL25002899 0.83 ALDH1A1 (0.65) ALDH1A1MAPTKDM4EHPGDHTR1A
SCHEMBL4946307 0.83 LMNA (0.57) ALDH1A1MAPTKDM4ECYP1A2HPGD
SCHEMBL28201857 0.83 ALDH1A1 (0.57) ALDH1A1MAPTKDM4EPKMCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023010192-A1 N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS EUROFARMA LABORATÓRIOS S.A. (BR) 2023-02-09 WO disclosed
US-7351843-B2 Furancarbonylguanidine derivatives, their preparation and pharmaceutical compositions containing them KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2008-04-01 US disclosed
US-20070299131-A1 Furancarbonylguanidine Derivatives, Their Preparation and Pharmaceutical Compositions Containing Them KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2007-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299131-A1 Furancarbonylguanidine Derivatives, Their Preparation and Pharmaceutical Compositions Containing Them SLC9A1, NHERF1, SLC5A1 ALDH1A1 297/4885MAPT 4846/4885KDM4E 3451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.